

1 SELF-MEDICATION WITH OVER-THE-COUNTER ANALGESICS: A SURVEY OF PATIENT
2 CHARACTERISTICS AND CONCERNS ABOUT PAIN MEDICATION

3 *Running title: Self-medication with OTC analgesics*

4 Els Mehuys¹, Geert Crombez², Koen Paemeleire³, Els Adriaens⁴, Thierry Van Hees⁵, Sophie Demarche⁵,
5 Thierry Christiaens⁶, Luc Van Bortel⁶, Inge Van Tongelen¹, Jean-Paul Remon¹ and Koen Bousser¹

6

7 ¹ Pharmaceutical Care Unit, Ghent University, Belgium

8 ² Department of Experimental-Clinical and Health Psychology, Ghent University, Belgium

9 ³ Department of Neurology, Ghent University Hospital, Belgium

10 ⁴ Adriaens Consulting, Aalter, Belgium

11 ⁵ Clinical Pharmacy Unit, University of Liege, Belgium

12 ⁶ Heymans Institute of Pharmacology, Ghent University, Belgium

13

14 **Corresponding author:**

15 E. Mehuys, Pharmaceutical Care Unit, Ghent University, Ottergemsesteenweg 460, B-9000 Ghent,
16 Belgium. Tel: +32 92648043. E-mail: els.mehuys@ugent.be

17

18

19 **Disclosures**

20 No funding sources were provided.

21 The authors have no conflicts of interest to declare.

22

23 **Keywords:** pain, self-medication, over-the-counter analgesics, community pharmacy

24

1 **ABSTRACT**

2 Pain is a common reason for self-medication with over-the-counter (OTC) analgesics. However, this self-
3 treating population has remained largely uncharacterized. This cross-sectional observational study
4 investigated individuals who self-medicate their pain with OTC analgesics to elucidate their pain
5 characteristics and medication use. In addition, presence of and risk factors for concerns about pain
6 medication were examined. The clinical profile of the participants (n=1889) was worse than expected with
7 long-standing pain complaints (median pain duration of 9 years), pain located at multiple body sites
8 (median of 4, and 13% with ≥ 10 painful body areas), about one third suffering from daily pain and about
9 40% experiencing substantial pain-related disability. Head (58.6% of sample), low back (43.6%) and neck
10 (30.7%) were the most common pain locations. About 73% had a physician diagnosis, mainly migraine and
11 osteoarthritis. Paracetamol (used by 68.6% of patients) and NSAID (46.8%) were the most frequently used
12 pain medications. About 40% of our sample showed substantial concern about the perceived need for
13 pain medication and the perceived potential for harmful effects (e.g. fear for addiction). These findings
14 highlight the importance for health professionals to systematically probe pain patients about their self-
15 medication practices and explore attitudes about pain medication.

16

17 **Perspective**

18 This study found that the clinical picture of people who self-medicate their pain with OTC analgesics
19 looked worse than expected. We also identified substantial concerns about pain medication. Therefore,
20 we recommend that health professionals systematically probe pain patients about their self-medication
21 practices and explore concerns about pain medication.

22

23

1 INTRODUCTION

2 Pain is a major healthcare problem. According to the most recent Global Burden of Disease Study, several
3 of the most common conditions are pain problems (such as tension-type headache, migraine and low back
4 pain). Also, pain is the leading cause of disability, with low back pain (first), migraine (second), neck pain
5 (sixth), and other musculoskeletal disorders (seventh) dominating the top ten of most important causes
6 of Years Lived with Disability (YLD).⁴

7 Medication is by far the most applied treatment method for pain. There are various medications available
8 for pain relief; these include over-the-counter (OTC) (e.g. paracetamol, aspirin, certain NSAIDs) as well as
9 prescription medications (e.g. NSAIDs, opioids). Over the past years, several population-based studies
10 have shown that self-medication with OTC analgesics is common^{2,7,22}. Prevalence estimates for the use
11 of OTC analgesics vary substantially between countries and according to definitions used. For example, in
12 the Norwegian HUNT-3 Study (2006-2008) the prevalence of using OTC analgesics at least once per week
13 in the last month was 47%⁷. A population survey of adults in Germany (2008-2011) found that 12.2% had
14 used an OTC analgesic in the previous week²². According to an analysis of Spanish data retrieved from the
15 2009 European Health Survey, 23.7% of persons with current pain self-medicated with OTC analgesics².
16 Self-medication of pain is common, and it will probably further increase as patients are stimulated to take
17 an active role in their ill-health. However, the individuals who self-medicate their pain are poorly
18 characterized. Population-based studies focus on determining prevalence of and factors associated with
19 use of OTC analgesics. Other studies investigated whether OTC analgesics are used safely and
20 appropriately^{12, 15, 21, 23, 26}. A thorough characterization of individuals who self-medicate their pain, has
21 not been performed yet. Many questions remain unanswered: Do these patients suffer from occasional
22 or chronic pain? From mild or severely disabling pain? Did they ever see a physician for their pain
23 complaints? Do they combine several pain medications? How often do they use their pain medication?
24 Do they have concerns about their pain medications (e.g. fear for addiction, tolerance or potential side

1 effects). Identification of these patient features may provide an avenue for improving care. This
2 information may be relevant for physicians, who are often not aware of the self-medication practices of
3 patients, as well as for community pharmacists, who can play a significant role in coaching self-medication.
4 In this study, we aimed to characterize the patients who self-medicate their pain. We conducted a
5 questionnaire-based survey among individuals who self-medicate pain complaints to elucidate their pain
6 characteristics and medication use. In addition, we determined presence of and risk factors for concerns
7 about pain medication.

8

9 **METHODS**

10 **Study design and study population**

11 The design of the present study has been described elsewhere ²⁰. Briefly, a cross-sectional observational
12 study was carried out from December 2012 until May 2013 in 202 community pharmacies in Belgium.
13 Community pharmacists consecutively invited pharmacy customers purchasing an OTC systemic analgesic
14 to participate in the study. Of note, persons presenting with a prescription for an OTC systemic analgesic
15 were not eligible. OTC systemic analgesics available in Belgium are paracetamol, acetylsalicylic acid,
16 ibuprofen 200-400 mg, naproxen 200 mg, and fixed dose combinations of simple analgesics with caffeine.
17 Persons were eligible when meeting the following inclusion criteria: purchasing the analgesic for
18 themselves, being aged ≥ 18 years, and suffering from pain during at least one full day in the last month.
19 It was planned to recruit 10 patients from each of the pharmacies.

20 In Belgium, the sale of OTC medicines is limited to pharmacies. Therefore, pharmacies are an ideal setting
21 to recruit a representative sample of persons with intentions to self-medicate.

22 The study protocol was approved by the Ethics Committees of Ghent University Hospital (for Flanders)
23 and CHU Liege (for Wallonia), and all patients gave written informed consent.

1 **Data collection**

2 Participants completed a self-administered questionnaire that was developed by the multidisciplinary
3 research team (a neurologist, a pain psychologist, a general practitioner, a clinical pharmacologist and
4 pharmacists). Participants answered questions on their sociodemographics (gender, age, marital status,
5 employment status and education level) and self-rated health (“How in general would you rate your
6 health?” with response options of “excellent, very good, good, fair, or poor”⁸). They indicated the
7 location(s) of their current pain on a full body manikin (front and back views; separated into 45 mutually
8 exclusive areas¹⁸; see online addendum) and reported physician diagnosis of current pain (if available),
9 pain duration and pain frequency. Pain disability was assessed by the Von Korff Pain Grading Scale²⁵. This
10 7-item questionnaire measures the degree of pain intensity and activity-related disability in the past three
11 months. Six items are scored on 11-point Likert scales (0 = “no pain/disability” and 10 = “worst pain/total
12 disability”). The seventh item asks for the number of days that pain has kept respondents from their
13 typical activities. Total scores classify respondents into one of four levels of pain disability (grade I: low
14 disability and low pain intensity, grade II: low disability and high pain intensity, grade III: high disability
15 and moderate limitation of activities, grade IV: high disability and severe limitation of activities).

16 Respondents also reported their current pain medication (OTC and prescribed) with frequency of use
17 during the prior month, and on whose advice they used the medication. Participants’ attitudes about pain
18 medication were determined using items from the Pain Medication Attitude Questionnaire (PMAQ)¹⁹.
19 The PMAQ assesses concerns held by patients regarding their pain medication. It has 47 items grouped
20 into seven domains (addiction, need, scrutiny, side effects, tolerance, mistrust and withdrawal). Each item
21 is scored on a 6-point Likert scale ranging from 0 (“never true”) to 5 (“always true”). We did not use the
22 complete PMAQ but selected a number of items that were considered of relevance to our study. Item
23 selection was done by a multidisciplinary consensus panel comprising a neurologist (KP), pain psychologist
24 (GC) and pharmacist (EM). Firstly, each member of the panel independently selected one or more items

1 from each PMAQ domain, based on their own expertise and experience. Secondly, the panel developed a
2 consensus on item selection during a face-to-face meeting (psychometric properties of the items from the
3 original PMAQ¹⁹ were used to support the discussion). This resulted in a final selection of ten PMAQ items
4 which are displayed in Table 4. We grouped the selected items according to the domains used in the
5 original PMAQ¹⁹. We calculated an overall PMAQ score as the mean of the ten individual item scores. As
6 two of the ten items only applied to patients who also use prescription pain medication (Table 4, items
7 marked with ^b), we also recalculated the overall PMAQ score by excluding these two items in determining
8 the mean of the individual item scores (i.e. mean of the eight individual item scores that could be
9 completed by all respondents).

10 **Statistical analysis**

11 Multivariate linear regression was used to evaluate the relationship between the level of concern about
12 medication (defined as the overall PMAQ score) and all other patient factors. The dependent variable was
13 the overall PMAQ score. Independent variables included age, gender, marital status, employment status,
14 education level, self-rated health, having a physician diagnosis of current pain, recent physician
15 consultation for pain (i.e. <6 months ago), number of pain regions, pain location (limited to the 3 most
16 common pain locations), pain duration, pain frequency, pain disability (Von Korff Pain Grading Scale),
17 number and type of pain medications (limited to the 3 most frequently used medications), and combined
18 use of OTC analgesics and prescription pain medication. We used a manual F-test-based backward
19 elimination method and nonsignificant factors ($P > 0.05$) were consecutively removed. Prior to the analysis,
20 variables were assessed for co-linearity. We also checked for relevant 2-way interactions between the
21 variables retained in the model. In addition, the analysis was redone using the recalculated version of
22 overall PMAQ score (i.e. mean of the eight individual item scores that could be completed by all
23 respondents). This was done to check whether or not this yielded the same patient factors associated with
24 overall PMAQ score. The analyses were performed by using R software (version 3.2.0; www.r-project.org).

1 RESULTS

2 In the 202 participating pharmacies, 10423 patients were consecutively contacted and screened for
3 eligibility, of which 3580 (34%) matched the inclusion criteria. About 53% (n=1889) of them agreed to
4 participate (Figure 1). The basic characteristics of the study population are displayed in Table 1.

5

6

7

8

9

10

11

12

13

14

15

16

17

18


19

20

21

22

23



23 Figure 1: Flow scheme of the participant recruitment process.

24

25

26

27

28

29

30

31

32

33

34

35

36

1 Table 1: Basic characteristics (N=1889)

Female sex ^a	1405 (74.8)
Age (years)	
Mean±SD	51.7±16.3
<25	125 (6.6)
25-40	340 (18.0)
41-55	674 (35.8)
56-70	486 (25.8)
>70	260 (13.8)
Marital status ^a	
Alone	364 (19.5)
Married or cohabiting	1177 (63.2)
Divorced	156 (8.4)
Widowed	166 (8.9)
Employment status ^a	
Employed	992 (52.8)
Unemployed	72 (3.8)
Retired	490 (26.0)
Not working due to ill health	100 (5.3)
Househusband/housewife	157 (8.4)
Student	68 (3.6)
Education level ^a	
Primary education	215 (11.4)
Secondary education	1073 (57.0)
Higher education	595 (31.6)
Self-rated health	
Excellent	47 (2.5)
Very good	258 (13.7)
Good	797 (42.2)
Fair	647 (34.3)
Poor	140 (7.4)

2 Data are presented as N (%), unless indicated otherwise.

3 ^a Subject to missing data

4

5

6

7

8

9

1 **Pain characteristics**

2 Participants marked a median of 4 painful areas (from 45) on the body manikin (Table 2). Head (58.6% of
3 the sample), low back (43.6%) and neck (30.7%) were the most common pain locations. About 60%
4 (n=1089) of patients had had their current pain complaints longer than 5 years. The median number of
5 pain days in the past 3 months was 36, and about one third (n=678) of participants reported daily pain for
6 the last 3 months. Forty-one percent experienced substantial pain-related disability (i.e. grade III or IV on
7 the Von Korff Pain Grading Scale).

8 The vast majority of participants (1742/1889; 92.2%) had consulted a physician for their current pain
9 complaints. Their last pain-related consultation was less than 6 months ago (1167/1742; 67.0%), between
10 6 and 12 months ago (237/1742; 13.6%), between 1 and 2 years ago (108/1742; 6.2%) and more than 2
11 years ago (183/1742; 10.5%). Some patients failed to remember (47/1742; 2.7%). Almost 75% (n=1386)
12 reported a physician diagnosis of current pain complaints. Migraine (436/1386; 31.5%), osteoarthritis
13 (226/1386; 16.3%), hernia (119/1386; 8.6%) and fibromyalgia (55/1386; 4.0%) were the most prevalent
14 diagnoses.

15
16
17
18
19
20
21
22
23
24
25
26
27
28

1 Table 2: Pain characteristics

N° of pain areas marked on body manikin (range 1-45)	
Median (IQR)	4 (5)
1-3	729 (38.6)
4-6	685 (36.3)
7-9	222 (11.8)
≥10	253 (13.4)
Pain location	
Abdomen	216 (11.4)
Chest	75 (4.0)
Foot	282 (14.9)
Forearm	172 (9.1)
Genital area	65 (3.4)
Hand	249 (13.2)
Head	1107 (58.6)
Hip	331 (16.5)
Low back	823 (43.6)
Lower leg/ankle	352 (18.6)
Neck	580 (30.7)
Shoulder	483 (25.6)
Upper arm	187 (9.9)
Upper back	207 (11.0)
Upper leg/knee	461 (24.4)
Pain duration (years) ^a	
Median (IQR)	9 (17)
0-5	742 (40.5)
6-10	301 (16.4)
11-15	229 (12.5)
16-20	130 (7.1)
>20	429 (23.4)
Pain frequency (n° of pain days in the past 3 months) ^a	
Median (IQR)	35 (80)
0-15	643 (34.2)
16-30	290 (15.4)
31-60	194 (10.3)
61-89	73 (3.9)
90	678 (36.1)
Pain disability (Von Korff Pain Grading Scale) ^{a,b}	
Grade I	445 (23.9)
Grade II	654 (35.2)
Grade III	398 (21.4)
Grade IV	362 (19.5)

2 Data are presented as N (%), unless indicated otherwise.

3 ^a Subject to missing data; ^b Grade I: low disability low intensity, Grade II: low disability high intensity, Grade III: high disability

4 moderately limiting, Grade IV: high disability severely limiting

1 **Use of pain medication**

2 The 1889 participants in this study were taking a total of 3795 pain medications, which corresponds to a
 3 mean of 2.0 (SD 1.1) per subject. Sixty-two percent only used OTC pain medication, and 38% combined
 4 OTC analgesics with pain medication on prescription. Paracetamol (used by 68.6% of the study
 5 population), NSAID (46.8%) and fixed dose combinations of simple analgesics with caffeine or codeine
 6 (21.9%) were the most frequently used medications (Table 3). Only few participants used preventive pain
 7 medication, such as certain antiepileptics or antidepressants (Table 3). Most medications were taken on
 8 medical doctor’s (2516/3746; 67.2%) or pharmacist’s advice (539/3746; 14.4%). Almost 30% (n=525) of
 9 the study population reported daily use of pain medication.

10

11 Table 3: Pain medication

	N (%)
Type	
Paracetamol	1296 (68.6)
Acetylsalicylic acid	73 (3.9)
Oral NSAIDs	884 (46.8)
Combination analgesics ^a	413 (21.9)
Caffeine-containing combinations	342 (18.1)
Codeine-containing combinations	87 (4.6)
Opioids	245 (13.0)
Triptans	101 (5.3)
Ergots	11 (0.6)
Muscle relaxants	47 (2.5)
Topical analgesics (NSAID or salicylates)	86 (4.6)
Antiepileptics	41 (2.2)
Antidepressants	38 (2.0)
Frequency of use (n° of medication days in past month)	
Median (IQR)	10 (25)
0-9	779 (41.2)
10-19	378 (20.0)
20-29	207 (11.0)
30	525 (27.8)

12 ^a Fixed dose combinations of simple analgesics with caffeine or codeine.

13

14

1 **Concerns about pain medication**

2 Our sample showed the highest level of concern about the need for pain medication. For example, in
 3 response to the item “I could cope without my pain medication(s)”, 61% indicated “never true”, “almost
 4 never true” or “seldom true”. In addition, a substantial proportion (about 30 to 40%) answered “often
 5 true”, “almost always true” or “always true” to the items about addiction, tolerance and side effects (Table
 6 4).

8 Table 4: Concerns about pain medication (items selected from the Pain Medication Attitude
 9 Questionnaire, PMAQ).

	Mean (SD) Likert score ^a	% of patients responding	
		<i>‘never true’, ‘almost never true’ or ‘seldom true’</i>	<i>‘often true’, ‘almost always true’ or ‘always true’</i>
Addiction			
“I am concerned that taking medication for a long time will lead to addiction”	1.7 (1.7)	61.9	38.1
Need			
“I would be unwilling to reduce my pain medication(s)”	2.2 (1.9)	54.5	45.5
“I could cope without my pain medication(s)”	3.3 (1.5)	60.9	39.0
“I feel that I need more pain medication(s) than my doctor is giving me” ^b	1.3 (1.5)	74.1	25.9
Scrutiny			
“I worry what others think about my use of pain medication(s)”	0.7 (1.2)	88.6	11.5
Side effects			
“I have concerns about the side effects from my pain medication(s)”	1.6 (1.5)	67.4	32.7
“I am afraid that I do not know enough about side effects”	1.6 (1.4)	68.8	31.2
Tolerance			
“It worries me that I have to increase the dose to get the same pain relief”	1.9 (1.7)	57.8	42.2
Mistrust			
“I am afraid that I am being prescribed the wrong pain medication(s)” ^b	0.9 (1.2)	85.6	14.4
Withdrawal			
“I worry that I will have some withdrawal symptoms if I stop my medication”	1.0 (1.5)	79.6	20.4

11 ^a Each item was answered on a 6-point Likert scale, ranging from 0 (“never true”) to 5 (“always true”).

12 ^b This item was only answered by patients taking prescribed medicines.

13

14

1 The results of the multivariate linear regression model for determining patient characteristics associated
2 with concerns about pain medication are shown in Table 5. Poorer self-rated health and higher levels of
3 disability were the factors most strongly associated with higher concerns about pain medication. Concerns
4 about pain medication were also higher in patients who had recently consulted a physician for their pain-
5 related complaints, patients using caffeine-containing combination analgesics, patients with headache,
6 patients combining OTC analgesics with prescription pain medication, patients using their pain medication
7 frequently and divorced patients.

8 Multivariate analysis using the recalculated version of overall PMAQ score yielded exactly the same
9 patient factors associated with concerns about pain medication (data not shown but available on request).

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

1 Table 5: Patient characteristics associated with concerns about pain medication ^a.
 2

	Estimate (SE) ^b	P value ^c
Self-rated health		<2.2 x e⁻¹⁶
Excellent	[Reference]	
Very good	0.06449 (0.11701)	0.581585
Good	0.19071 (0.11134)	0.086895
Fair	0.34344 (0.11445)	0.002730
Poor	0.48084 (0.13036)	0.000232
Pain disability (Von Korff Pain Grading Scale)		<2.2 x e⁻¹⁶
Grade I	[Reference]	
Grade II	0.16773 (0.04649)	0.000317
Grade III	0.29724 (0.05387)	3.92 x e ⁻⁸
Grade IV	0.46152 (0.06094)	5.75 x e ⁻¹⁴
Recent physician consultation for pain (i.e. <6 months ago)		2.37 x e⁻⁷
No	[Reference]	
Yes	0.08893 (0.03935)	0.023588
Uses caffeine-containing combination analgesics		1.73 x e⁻⁶
No	[Reference]	
Yes	0.21043 (0.04647)	6.34 x e ⁻⁶
Headache as pain location		2.143 x e⁻⁶
No	[Reference]	
Yes	0.14894	5.93 x e ⁻⁵
Combines OTC analgesics with prescription pain medication		9.014 x e⁻⁵
No	[Reference]	
Yes	0.11493 (0.03776)	0.002372
Frequency of pain medication use		0.0001161
≤7 medication days in past month	[Reference]	
8-15	0.05387 (0.04768)	0.258656
>15	0.19308 (0.04688)	3.98 x e ⁻⁵
Marital status		0.0007470
Alone	[Reference]	
Married or cohabiting	0.06248 (0.04428)	0.158407
Divorced	0.17807 (0.07085)	0.012046
Widowed	-0.05215 (0.07011)	0.457106

3 ^a Table reports results of a multivariate linear regression model of patient factors associated with concerns about pain medication
 4 (defined as the overall PMAQ score). The dependent variable was the overall PMAQ score. Independent variables included age,
 5 gender, marital status, employment status, education level, self-rated health, having a physician diagnosis of current pain
 6 complaints, recent physician consultation for pain (<6 months ago), n° of pain areas, pain location, pain duration, pain frequency,
 7 pain disability (Von Korff Pain Grading Scale), n° and type of pain medications, and combining OTC analgesics with prescription
 8 pain medication.

9 ^b Estimates indicate how much the dependent variable (i.e. overall PMAQ score) varies with the independent variable, when all
 10 other independent variables are held constant. The higher the absolute value of the estimate, the stronger the effect on overall
 11 PMAQ score. For example, there is an increase in overall PMAQ score of 0.48084 in patients with poor self-rated health compared
 12 to patients with excellent self-rated health. P values for the estimates are displayed in column 'P values' (regular font, not bold).

13 ^c P values in bold represent p values for the F-test. These indicate the strength of association of the patient factor with overall
 14 PMAQ score; the lower the p value, the stronger the association with overall PMAQ score. In this Table, patient factors are
 15 arranged in decreasing order of strength of association with overall PMAQ score. P values in regular font (not bold) are P values
 16 for the estimates (see column 'Estimate (SE)').
 17
 18

1 DISCUSSION

2 This study aimed to characterize patients who self-medicate with OTC analgesics for their pain. There
3 were some interesting and surprising results. The head was by far the most prevalent pain location, with
4 almost 60% reporting headache. Moreover, almost one quarter of the total sample reported to be
5 diagnosed with migraine. The actual migraine prevalence in our study population is likely to be higher
6 because migraine is generally known to be an underdiagnosed condition ^{3,9,16}. Altogether these findings
7 confirm that headache is a very common reason for self-medication with OTC analgesics. Although often
8 viewed as a trivial complaint, headache can cause significant distress with substantial impact on quality
9 of life ⁴ as well as economic burden due to lost productivity and direct healthcare costs ^{1,13}. Therefore, our
10 findings call for a well-organized and effective integrated care pathway for headache that is focused
11 primarily within the primary care setting, including adequately educated health professionals that are
12 easily accessible to the public and that work in cooperation with specialist care ⁵. Community pharmacists
13 can play a key role in such care pathway. They are well-placed to detect and advise people who self-
14 medicate (e.g. informing about the appropriate use of OTC analgesics, discouraging overuse, timely
15 referral to a physician).

16 The overall clinical picture of our sample is worse than expected, with long-standing pain complaints
17 (median pain duration of 9 years), pain located at multiple body sites (median of 4, and 13% with ≥ 10
18 painful body areas), about one third suffering from daily pain and about 40% experiencing substantial
19 pain-related disability. Intuitively, one would associate the use of OTC analgesics with occasional and/or
20 mild pain. This, however, clearly was not the case in the present study. One might assume that the
21 considerable level of pain-related disability is caused by the high number of individuals with headache in
22 the sample. Headache is both common and disabling. However, the percentage of participants with higher
23 disability levels (i.e. grade III or IV on the Von Korff Pain Grading Scale) in the subgroup with headache

1 and the subgroup without headache was found to be quasi identical (39.4% vs 43.6%), thus rejecting this
2 hypothesis.

3 The sample's medication use seems not to match with their clinical profile. It is remarkable that only very
4 few respondents consumed preventive pain medication. The use of migraine-specific acute medication
5 (triptans) was also low (5%), despite the considerable number of migraineurs in the sample. The question
6 is, why do people with disabling chronic pain self-treat with OTC analgesics? Our participants seem not
7 completely lapsed from medical care: 80% had consulted a physician for their pain complaints in the past
8 year. So exclusive self-medication without seeing a doctor cannot explain our findings. The easy
9 accessibility of OTC drugs (i.e. no doctor's consultation required) could be an explanation. Another
10 possible explanation, however, may lie in the participants' concerns about pain medication. The results of
11 the PMAQ questionnaire revealed a high perceived need for pain medication and substantial concerns
12 about (perceived) potential harms (i.e. addiction, tolerance and side effects). From this perspective,
13 individuals with chronic pain might use OTC analgesics as a harm reduction strategy, by seeking some level
14 of pain relief while also avoiding or reducing the potential harms associated with prescription pain
15 medication. Such harm reduction strategy has been described previously by chronic pain sufferers in a
16 qualitative interview study ¹⁰. Participants of that qualitative study cited several reasons to avoid
17 prescription pain medication, including: (a) maintaining awareness of pain to monitor symptoms and
18 avoid further damage; (b) saving medication for when really needed; (c) perception of medication as less
19 effective if taken often; (d) concern that pain medications impair ability to function normally; and (e)
20 concern about addiction. They regarded prescription pain medication as a poor coping strategy, as they
21 know pain would return as soon as medication wore off. Instead, participants chose to use OTC pain
22 medications, still with reluctance, to mitigate downside risks while still gaining some level of relief ¹⁰. Such
23 benefit/risk trade-offs are in line with the necessity-concerns framework that is currently prevailing in
24 drug adherence research ^{11, 14}. There is evidence that necessity and concern beliefs about medicines are

1 correlated with adherence in a wide variety of conditions ^{11,14}. In addition, similar observations have been
2 reported by a recent study about migraine sufferer's willingness to take migraine prophylactic medication
3 ²⁴. Migraine patients were informed about the likelihood of experiencing side effects for several migraine
4 prophylactic drugs and were subsequently asked if they would be willing to take the medication for a
5 given headache reduction level. Strikingly, less than 60% of participants were willing to take any of these
6 medications when they would provide about 50% reduction in headache days/month, while this is a
7 realistic and clinically relevant outcome with migraine prophylaxis ²⁴. Moreover, the idea of taking a pill
8 each and every day for many years or even lifelong to prevent only half of migraine attacks might also
9 contribute to patients' reluctance towards preventive medication, especially in young patients ⁶.

10 The current study also determined patient characteristics associated with concerns about medication. We
11 were surprised to find that sociodemographic factors were not associated with medication-related
12 concerns (except for marital status: divorced people were estimated to have slightly higher concerns than
13 people who live alone). So from a clinician's point of view, it is important to realize that any patient can
14 have worries about pain medication; irrespective of gender, age, employment status or education level.

15 The factors that were most strongly associated with concerns about medication were linked with the
16 patient's clinical condition, i.e. self-rated health status and disability level. More recent consultations with
17 the medical doctor, which might be regarded as indicator for severity of the pain condition or for anxiety
18 or depressive feelings, were also associated with higher concerns. It is unclear why having headache was
19 associated with higher concerns. One possible explanation might be the recent increase in public attention
20 for medication-overuse headache (a worsening of a pre-existing headache owing to overuse of pain
21 relieving medication). Knowing that inappropriate use of pain medication is capable of deteriorating
22 headaches increase concern. The other factors associated with increased concerns are linked to the
23 medication itself, i.e. the use of combination analgesics, concomitant use of prescription pain medication
24 and a high frequency of use.

1 The data from this study should be considered in the context of its limitations. First, we used self-reported
2 data, which may be subject to recall bias. Physician diagnoses were also self-reported, so these should be
3 interpreted with caution. For example, patients may have a tendency to report “any bad headache” as a
4 migraine headache. However, it is reassuring that there is considerable evidence for the validity of self-
5 reported diagnosis of migraine ¹⁷. Second, a relatively high number of potential participants refused to
6 participate in the study (47%). Potential bias caused by those who refused participation could not be
7 assessed as our Ethics Committee prohibits data collection in study refusers. However, we did record
8 reasons for refusal (‘no time’ and ‘no interest’ were the most commonly given reasons). Third, we did not
9 use the complete version of the PMAQ questionnaire because many items were not relevant for people
10 who only use OTC analgesics. Fourth, we did not assess whether the physician was aware of patients’ use
11 of OTC analgesics.

12 A strength of this study is its large sample size in a population that is largely uncharacterized so far.
13 Another asset is the exploration of patients’ attitudes and concerns towards pain medication, as
14 recognizing such concerns is key to providing patient-centered care.

15 Our study design and setting aimed to minimize the risk of selection bias. However, the worse than
16 expected clinical picture may suggest a selection bias by severity as we only included individuals suffering
17 from pain during at least **one full day** in the past month. This inclusion criterion was chosen purposively
18 to select patients with longer-lasting pain attacks because they are clinically more relevant and may be
19 most in need of care. In addition, patients with more severe pain complaints may have been more
20 motivated to participate in the study, which could be another potential reason for the worse than
21 expected clinical profile. It is also relevant to note that only pharmacy customers coming themselves to
22 the pharmacy were eligible for participation, so patients with poor mobility who rely on another person
23 for their medication purchase will not be represented in our sample. Our data may thus reflect an
24 underestimation of the situation in real life. In light of this, our findings may not be generalizable to all

1 individuals using OTC analgesics. Another possible limitation of generalizability is that our sample was
2 predominantly female (75%). This is probably related to the fact that chronic pain and particularly
3 headache are more common in women. Regarding generalizability to other countries with different health
4 care systems, it is important to bear in mind that patients' out-of-pocket cost for doctor's visits and
5 medication are low in Belgium (due to a compulsory health insurance that covers the entire population
6 and with a broad benefits package). In countries with less accessible health care systems, people with pain
7 might be less likely to seek medical care, and thus rates of doctor's consultation and diagnosis as well as
8 the use of prescription pain medication may be lower.

9 In conclusion, we observed a high prevalence of headache as well as a high prevalence of long-standing,
10 frequent and disabling pain among adults who self-medicate pain complaints (that at least lasted one full
11 day). Furthermore, we noticed a high perceived need for pain medication and substantial concerns about
12 its potential harms. Based on our findings we recommend that health professionals systematically and
13 concretely probe pain patients about their self-medication practices (including dose and dosing
14 frequency), and explore attitudes about pain medication in an open and nonjudgmental way, at the
15 initiation of therapy and during (long-term) follow-up.

16 **ACKNOWLEDGEMENTS**

17 We thank the pharmacies and patients who participated in this study.

18

19

20

21

22

1 REFERENCES

- 2 1. Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, Varon SF, Blumenfeld AM,
3 Katsarava Z, Pascual J, Lanteri-Minet M, Cortelli P, Martelletti P. Cost of healthcare for patients
4 with migraine in five European countries: results from the International Burden of Migraine Study
5 (IBMS). *The journal of headache and pain*. 13:361-378, 2012
- 6 2. Carrasco-Garrido P, de Andres AL, Barrera VH, Jimenez-Trujillo I, Fernandez-de-Las-Penas C,
7 Palacios-Cena D, Garcia-Gomez-Heras S, Jimenez-Garcia R. Predictive factors of self-medicated
8 analgesic use in Spanish adults: a cross-sectional national study. *BMC Pharmacol Toxicol*. 15:36,
9 2014
- 10 3. Cevoli S, D'Amico D, Martelletti P, Valguarnera F, Del Bene E, De Simone R, Sarchielli P, Narbone
11 M, Testa L, Genco S, Bussone G, Cortelli P. Underdiagnosis and undertreatment of migraine in
12 Italy: a survey of patients attending for the first time 10 headache centres. *Cephalalgia : an
13 international journal of headache*. 29:1285-1293, 2009
- 14 4. Collaborators GBD 2016 Disease and Injury Incidence and Prevalence. Global, regional, and
15 national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195
16 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*.
17 390:1211-1259, 2017
- 18 5. European Brain Council. Value of treatment - Policy White Paper. Available at:
19 [http://www.braincouncil.eu/wp-](http://www.braincouncil.eu/wp-content/uploads/2017/06/EBC_white_policy_paper_DEF26072017_Low.pdf)
20 [content/uploads/2017/06/EBC_white_policy_paper_DEF26072017_Low.pdf](http://www.braincouncil.eu/wp-content/uploads/2017/06/EBC_white_policy_paper_DEF26072017_Low.pdf)
- 21 6. D'Amico D, Tepper SJ. Prophylaxis of migraine: general principles and patient acceptance.
22 *Neuropsychiatric disease and treatment*. 4:1155-1167, 2008
- 23 7. Dale O, Borchgrevink PC, Fredheim OM, Mahic M, Romundstad P, Skurtveit S. Prevalence of use
24 of non-prescription analgesics in the Norwegian HUNT3 population: Impact of gender, age,
25 exercise and prescription of opioids. *BMC Public Health*. 15:461, 2015
- 26 8. DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P. Mortality prediction with a single general self-
27 rated health question. A meta-analysis. *Journal of general internal medicine*. 21:267-275, 2006
- 28 9. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute
29 and preventive treatment for migraine in the United States: results from the American Migraine
30 Prevalence and Prevention study. *Headache*. 47:355-363, 2007
- 31 10. Eaves ER. "Just Advil": Harm reduction and identity construction in the consumption of over-the-
32 counter medication for chronic pain. *Social science & medicine (1982)*. 146:147-154, 2015
- 33 11. Foot H, La Caze A, Gujral G, Cottrell N. The necessity-concerns framework predicts adherence to
34 medication in multiple illness conditions: A meta-analysis. *Patient education and counseling*.
35 99:706-717, 2016
- 36 12. Grezy-Chabardes C, Fournier JP, Dupouy J, Poutrain JC, Oustric S. Patients' Knowledge About
37 Analgesic-Antipyretic Medications Purchased in Community Pharmacies: A Descriptive Study. *J
38 Pain Palliat Care Pharmacother*. 29:334-340, 2015
- 39 13. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli
40 C, Fratiglioni L, Gannon B, Jones DH, Jenum P, Jordanova A, Jonsson L, Karampampa K, Knapp M,
41 Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A,
42 Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen
43 HC, Stovner LJ, Vallat JM, Van den Bergh P, van Os J, Vos P, Xu W, Wittchen HU, Jonsson B, Olesen
44 J. Cost of disorders of the brain in Europe 2010. *European neuropsychopharmacology : the journal
45 of the European College of Neuropsychopharmacology*. 21:718-779, 2011

- 1 **14.** Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients'
2 adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic
3 review of the Necessity-Concerns Framework. *PloS one*. 8:e80633, 2013
- 4 **15.** Kaufman DW, Kelly JP, Rohay JM, Malone MK, Weinstein RB, Shiffman S. Prevalence and
5 correlates of exceeding the labeled maximum dose of acetaminophen among adults in a U.S.-
6 based internet survey. *Pharmacoepidemiol Drug Saf*. 21:1280-1288, 2012
- 7 **16.** Kernick D, Stapley S, Hamilton W. GPs' classification of headache: is primary headache
8 underdiagnosed? *The British journal of general practice : the journal of the Royal College of*
9 *General Practitioners*. 58:102-104, 2008
- 10 **17.** Lenert LA, Looman T, Agoncillo T, Nguyen M, Sturley A, Jackson CM. Potential validity of
11 conducting research on headache in internet populations. *Headache*. 42:200-203, 2002
- 12 **18.** Margolis RB, Tait RC, Krause SJ. A rating system for use with patient pain drawings. *Pain*. 24:57-
13 65, 1986
- 14 **19.** McCracken LM, Hoskins J, Eccleston C. Concerns about medication and medication use in chronic
15 pain. *The journal of pain : official journal of the American Pain Society*. 7:726-734, 2006
- 16 **20.** Mehuys E, Paemeleire K, Crombez G, Adriaens E, Van Hees T, Demarche S, Christiaens T, Van
17 Bortel L, Van Tongelen I, Remon JP, Boussery K. The heterogeneity of headache patients who self-
18 medicate: a cluster analysis approach. *Pain*. 157:1464-1471, 2016
- 19 **21.** Pottegard A, Kviesgaard AK, Hesse U, Moreno SI, Hansen JM. Patient characteristics among users
20 of analgesic over-the-counter aspirin in a Danish pharmacy setting. *Int J Clin Pharm*. 36:693-696,
21 2014
- 22 **22.** Sarganas G, Buttery AK, Zhuang W, Wolf IK, Grams D, Rosario AS, Scheidt-Nave C, Knopf H.
23 Prevalence, trends, patterns and associations of analgesic use in Germany. *BMC Pharmacol*
24 *Toxicol*. 16:28, 2015
- 25 **23.** Shiffman S, Rohay JM, Battista D, Kelly JP, Malone MK, Weinstein RB, Kaufman DW. Patterns of
26 acetaminophen medication use associated with exceeding the recommended maximum daily
27 dose. *Pharmacoepidemiol Drug Saf*. 24:915-921, 2015
- 28 **24.** Turner DP, Golding AN, Houle TT. Using a graphical risk tool to examine willingness to take
29 migraine prophylactic medications. *Pain*. 157:2226-2234, 2016
- 30 **25.** Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. *Pain*. 50:133-
31 149, 1992
- 32 **26.** Wilcox CM, Cryer B, Triadafilopoulos G. Patterns of use and public perception of over-the-counter
33 pain relievers: focus on nonsteroidal antiinflammatory drugs. *J Rheumatol*. 32:2218-2224, 2005

36 FIGURE AND TABLE LEGENDS

37
38 Figure 1: Flow scheme of the participant recruitment process.

39 Table 1: Basic characteristics (N=1889).

40 Table 2: Pain characteristics.


41 Table 3: Pain medication

42 Table 4: Concerns about pain medication (items selected from the Pain Medication Attitude
43 Questionnaire, PMAQ).

44 Table 5: Patient characteristics associated with concerns about pain medication ^a.

1 ADDENDUM: Full body manikin used to define the 45 pain sites in the front and the back ¹⁸.

2



3